Results 221 to 230 of about 1,191,327 (361)

Patient‐specific modifiers of survival benefit in cardiac resynchronization therapy ‐ A multicentre interaction analysis

ESC Heart Failure, EarlyView.
Abstract Background Cardiac resynchronization therapy (CRT) is a key intervention for patients with heart failure. The choice between a CRT with defibrillator therapy (CRT‐D) and a CRT with pacemaker (CRT‐P) is influenced by individual clinical characteristics.
Bert Vandenberk, Marius Brusselmans, Gabor Voros, Pieter Martens, Sebastian Ingelaere, Pascal Betschart, Jens‐Uwe Voigt, Matthias Dupont, Alexander Breitenstein, Jan Steffel, Rik Willems, Frank Ruschitzka, Wilfried Mullens, Sander Trenson, Stephan Winnik   +14 more
wiley   +1 more source

Risk factors of pediatric steroid-induced ocular hypertension. [PDF]

Graefes Arch Clin Exp Ophthalmol
Takano F, Ueda K, Yamada-Nakanishi Y, Nakamura M.   +3 more
europepmc   +1 more source

The Pattern Electroretinogram in Glaucoma and Ocular Hypertension [PDF]

, 2006

openalex   +1 more source

Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology

European Journal of Heart Failure, EarlyView.
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a ...
Maurizio Volterrani, Geza Halasz, Stamatis Adamopoulos, Pier Giuseppe Agostoni, Javed Butler, Andrew J.S. Coats, Alan Cohen‐Solal, Wolfram Doehner, Gerasimos Filippatos, Ewa Jankowska, Carolyn S.P. Lam, Ekaterini Lambrinou, Lars H. Lund, Giuseppe Rosano, Marco Metra, Stefania Paolillo, Pasquale Perrone Filardi, Amina Rakisheva, Gianluigi Savarese, Petar Seferovic, Carlo Gabriele Tocchetti, Massimo Piepoli   +21 more
wiley   +1 more source

Neuroprotective Effect of the Combination of Citicoline and CoQ10 in a Mouse Model of Ocular Hypertension. [PDF]

Antioxidants (Basel)
Matamoros JA, Rubio-Casado S, Fernández-Albarral JA, Martínez-López MA, Salobrar-García E, Marco EM, Paleo-García V, de Hoz R, López-Cuenca I, Elvira-Hurtado L, Sánchez-Puebla L, Ramírez JM, Salazar JJ, López-Gallardo M, Ramírez AI.   +14 more
europepmc   +1 more source

Long-term Intraocular Pressure Fluctuations and Risk of Conversion from Ocular Hypertension to Glaucoma [PDF]

, 2007
Felipe A. Medeiros, Robert N. Weinreb, Linda M. Zangwill, Luciana M. Alencar, Pamela A. Sample, Cristiana Vasile, Christopher Bowd   +6 more
openalex   +1 more source

Ocular Hypertension

Definitions, 2020
A. Guide, Russell Young
semanticscholar   +1 more source

The transcriptional profile of iron deficiency in patients with heart failure: Heme‐sparing and reduced immune processes

European Journal of Heart Failure, EarlyView.
The analysis workflow, findings and potential clinical consequences of iron deficiency in heart failure (HF). From 881 patients with worsening HF, whole blood transcriptome was analysed using the Affymetrix Human Transcriptome Array (HTA) 2.0. Subjects were stratified according to their transferrin saturation (TSAT) levels as iron‐deficient (TSAT <20%)
Niels Grote Beverborg, Ridha I.S. Alnuwaysir, George Markousis‐Mavrogenis, Martijn F. Hoes, Haye H. van der Wal, Simon P.R. Romaine, Mintu Nath, Andrea Koekoemoer, John G.F. Cleland, Chim C. Lang, Stefan D. Anker, Kenneth Dickstein, Marco Metra, Leong L. Ng, Dirk J. van Veldhuisen, Adriaan A. Voors, Nilesh J. Samani, Peter van der Meer   +17 more
wiley   +1 more source

Selective Laser Trabeculoplasty After Medical Treatment for Glaucoma or Ocular Hypertension.

JAMA Ophthalmol
Konstantakopoulou E, Gazzard G, Garway-Heath D, Adeleke M, Ambler G, Vickerstaff V, Bunce C, Nathwani N, Barton K, LiGHT Trial Study Group.   +9 more
europepmc   +1 more source

Latanoprostene Bunod 0.024% Early Experience Program (LEEP): A Canadian Initiative for Open-Angle Glaucoma and Ocular Hypertension. [PDF]

Ophthalmol Ther
Yan D, Hutnik CML, Harasymowycz P.
europepmc   +1 more source